Amir Nashat

Amir Nashat joined Polaris Partners in 2002 and is a partner in the Boston office. He focuses on portfolio company executive roles as well as investing in healthcare companies

Amir currently represents Polaris as a director of CAMP4 Therapeutics, Dewpoint Therapeutics, Matter Neuroscience, and Paratus Sciences.

Additionally, Amir has served as a director of Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Fate Therapeutics (NASDAQ: FATE), Freenome, Living Proof (Unilever), Metacrine Therapeutics, Morphic Therapeutic (Lilly), Primmune Therapeutics, Promedior Pharmaceuticals (Roche), Receptos (Celgene), Scholar Rock (NASDAQ: SRRK), Selecta Biosciences (NASDAQ: SELB), Sun Catalytix (Lockheed Martin), Syros Pharmaceuticals (NASDAQ: SYRS), and TARIS Biomedical (J&J). He was also CEO of Polaris portfolio companies Dewpoint, Jnana, Living Proof, Olivo Labs, Paratus Sciences, and Sun Catalytix.

Amir was also CEO of Polaris portfolio companies Jnana, Living Proof, Olivo Labs, Paratus Sciences, and Sun Catalytix.

Amir serves on the Investment Committee of Mass General Brigham Ventures and helped launch the MIT Sandbox Innovation Fund as its founding president. He serves on the board of Boston Ballet and Hertz Foundation.

He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”

Prior to joining Polaris, Amir completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley